Solera Health recently launched a program that aims to help patients who are interested in GLP-1s gain access to lifestyle change support. It also provides educational materials on GLP-1s.
Hello Alpha launched Ahead with Alpha, a weight management program for employers. It offers access to primary care providers trained in obesity care, medication management through weight loss drugs like GLP-1s, nutrition counseling with a registered dietitian and progress tracking.
There are a number of criteria for selecting the best autism therapy centers. Parents choosing a facility or professionals seeking to improve their offerings should consider certain standards to ensure the right fit.
Alfie Health's $2.1 million seed funding was led by Y Combinator and Nina Capital. It included participation from Goodwater Capital, Phoenix Investment Club and several angel investors.
Through LifeMD's new weight management program, consumers can gain access to GLP-1 prescriptions like Ozempic and Wegovy, clinical support, lab testing, education and more.
Found for Business is an evidence-based obesity care program that prescribes 13 different medications (including GLP-1s) in 60 different combinations. It combines the medication with support from providers, coaching and an app that offers meal and activity tracking.
WeightWatchers will acquire Sequence, a platform that allows patients to have virtual appointments with a clinician, gives access to a dietitian and fitness coaching and provides prescription medications, including Ozempic and Wegovy. The deal is anticipated to close during the second quarter of 2023, and WeightWatchers will pay the net purchase price of $106 million.
Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.
Obesity is a disease, and America’s healthcare providers and hospital systems must be part of changing how we treat it. That means many of us in the health ecosystem must reexamine how we view patients with excess weight.
The deal will give Livongo the ability to provide a wider spectrum of services for employer wellness and health plan members.
BAROnova has brought in significant capital to fund its U.S. clinical study of its endoscopically delivered weight-loss device, the TransPyloric Shuttle (TPS).